Drugs / PIPE-791
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06810245 | Feb 2025 → Jan 2026 | chronic pain syndrome | Contineum Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06683612 | Dec 2024 → Jun 2025 | idiopathic pulmonary fibrosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Contineum Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05983939 | Jun 2023 → Feb 2024 | multiple sclerosis | Contineum Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07284459 | Jan 2026 → May 2028 expected | idiopathic pulmonary fibrosis | Contineum Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIPE-791 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06810245 ↗ |
| Action | Inhibit | “lysophosphatidic acid receptor 1 (LPAR1) antagonist” PMID 42370792 ↗ Jun 2026 |
| Modality | Small molecule | “compound 21 that possessed a unique urea scaffold” PMID 42370792 ↗ Jun 2026 |
| Route | Oral | “Single and multiple ascending oral doses of PIPE-791 tablets.” NCT05983939 ↗ |
| Target | LPAR1 | “lysophosphatidic acid receptor 1 (LPAR1) antagonist” PMID 42370792 ↗ Jun 2026 |